As discussed previously, cancers with a loss of PBRM1 are more responsive to DNA damage and immune checkpoint inhibitors [50,51,52], suggesting that small molecule inhibitors selective for PBRM1 would be therapeutically useful. Here, PBRM1 is linked to cancer.